Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 54: 388-395, 2008. First published December 18, 2007; 10.1373/clinchem.2007.094623
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2007.094623v1
54/2/388    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coste, T. C.
Right arrow Articles by Leal, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coste, T. C.
Right arrow Articles by Leal, T.
Related Collections
Right arrow Nutrition
(Clinical Chemistry. 2008;54:388-395.)
© 2008 American Association for Clinical Chemistry, Inc.

Nutrition

Influence of Pancreatic Status and Sex on Polyunsaturated Fatty Acid Profiles in Cystic Fibrosis

Thierry Charles Coste1, Gladys Deumer1, Gregory Reychler2, Patrick Lebecque3, Pierre Wallemacq1,a and Teresinha Leal1

1 Clinical Chemistry, 2 Rehabilitation and Physical Medicine, and 3 Pediatric Pulmonology, Université Catholique de Louvain, B-1200 Brussels, Belgium.

aAddress correspondence to this author at: Clinical Chemistry, 10 Ave. Hippocrate, BP 6720, B-1200 Brussels, Belgium. Fax +32 2 764 6932; e-mail wallemacq{at}lbcm.ucl.ac.be.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Background: Some but not all studies have reported abnormal polyunsaturated fatty acid composition in cystic fibrosis (CF) patients. We investigated the influence of pancreatic status and sex on the fatty acid profile in plasma and erythrocyte membranes in patients with CF.

Methods: After a 1-step transesterification with acetyl chloride on plasma and washed erythrocyte membranes, we quantified fatty acid methyl esters by use of GC-MS in 124 CF patients and 80 age-matched healthy controls. In the CF group, mean (SD) age was 17.5 (11.3) years, and 51.6% were male. Pancreatic insufficiency was diagnosed in 78% of the CF population.

Results: A decrease in docosahexaenoic acid concentrations was observed in CF patients independently of pancreatic status. Pancreatic insufficient CF patients displayed lower concentrations of linoleic acid and arachidonic acid and higher concentrations of dihomo-{gamma}-linolenic acid and eicosatrienoic acid (mead acid) in plasma and erythrocyte membranes compared with healthy controls and pancreatic sufficient CF patients. Male CF patients had significantly lower docosahexaenoic acid and higher eicosatrienoic acid in plasma and erythrocyte membranes compared with female CF patients.

Conclusions: These results support the concept that multiple abnormalities of polyunsaturated fatty acid composition participate in the CF disease phenotype and that pancreatic status plays a major role in such abnormalities. Moreover, patient sex influences the polyunsaturated fatty acid spectrum in CF, with more marked abnormalities in males.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Cystic fibrosis (CF)1 is the most prevalent autosomal recessive inherited disease in white populations. Mutations affecting a single gene, located on the long arm of chromosome 7 and encoding for the CF transmembrane conductance regulator (CFTR) protein, are responsible for the clinical manifestations of the disease (1). CFTR is expressed in the apical membrane of various epithelial cells and functions as a phosphorylation-regulated chloride channel and as a regulator of other ion channels (2). The most common CF mutation, a deletion of a single phenylalanine residue at position 508 ({Delta}F508), causes defective synthesis and folding of the mutant protein that fails to reach the apical membrane of many epithelial cell types (3).

Despite impressive advances in understanding the molecular basis of CF, life expectancy is still limited. Pulmonary disease accounts for most of the morbidity and mortality (4). The majority of CF patients have pancreatic exocrine insufficiency, even in early infancy, which, if untreated, leads to fat malabsorption and malnutrition (5). Pancreatic insufficiency can be alleviated by oral supplementation of pancreatic enzymes; however, many patients continue to experience a degree of steatorrhea, with fat absorption ranging from 80% to 90% of their dietary fat intake (6). Genotype-phenotype correlation in CF is highly variable (7), with modifier genes and environmental factors playing a part in determining severity of the disease.

The prognosis of CF has improved steadily over the past 5 decades, mainly because of aggressive treatment before the onset of irreversible pulmonary changes. Long-term survival is significantly better in patients without pancreatic insufficiency. Increased survival rates of patients with CF have revealed the development of related metabolic alterations. Among these, abnormal blood polyunsaturated fatty acid (PUFA) concentrations have been reported (8). These alterations were first reported to be related to essential fatty acid deficiency (EFAD) (9) or defective essential fatty acid metabolism (10). More recently, an imbalance between arachidonic acid (AA) and docosahexaenoic acid (DHA), rather than a deficiency in PUFAs, was described in an animal model of CF (11) and in patients (12). However, it emerges from previous studies that PUFA status is quite variable in CF and discrepancies can result from a variety of factors such as small population sample sizes, inappropriate age-matching controls, different blood compartments, and analytical techniques (8). To our knowledge, only one work from a Swedish group has reported plasma phospholipid fatty acid composition in a CF population larger than 100 patients (13). As these Swedish CF patients regularly benefit from intralipid treatment (intravenous essential fatty acids course), data obtained from this study may not be representative of a nontreated CF patient population.

This study was designed to test the hypothesis that pancreatic status and sex influence the composition of PUFAs in plasma and erythrocyte membranes in patients with CF.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
study participants
Clinical data were collected from 124 CF patients meeting the consensus-statement requirement for the diagnosis of this disease (14) and regularly attending our CF reference center in Brussels. Pancreatic status was determined by fat or elastase contents in stool samples: patients currently not treated by pancreatic enzyme replacement with fecal fat <7% (wt/wt) of the amount of dietary fat or with fecal elastase >200 µg/g were defined as pancreatic sufficient (15)(16), the others as pancreatic insufficient. Respiratory involvement was assessed by lung function testing. Forced expiratory volume in 1 s (FEV1) was expressed as percentage of the predicted value for age, sex, and height (17). Patients with persistent positive cultures of Pseudomonas aeruginosa from on average 2 sputum collections over at least 6 consecutive months were classified as chronically infected. Nutritional status was simply assessed by body mass index [BMI, ratio of body weight (kg) to height (m2)], and BMI z score was calculated on the basis of BMI curves from a reference population (18). CF-related diabetes was defined by requirement for insulin therapy. Among the patients, 61 were homozygous for the {Delta}F508 mutation, 51 were heterozygous for the {Delta}F508 mutation, and 12 had no {Delta}F508-mutated allele. Eighty age-matched healthy controls were enrolled. Our Institutional Research Ethics Committee approved the study, and all study participants signed informed consent forms before being enrolled.

chemicals
Fatty acid methyl esters were of the highest available grade from either Sigma Chemical or Nu-Chek Prep. Solvents were purchased from Merck. Other chemicals and organic products were purchased from Sigma Chemical.

blood sample preparation
Blood samples (5 mL on EDTA), collected after fasting, were centrifuged at 1000g for 15 min at 4 °C. The plasma was collected and stored at –80 °C for subsequent analysis. Erythrocyte pellet was lysed with 40 mL Tris buffer (11 mmol/L, pH 7.4), centrifuged at 40 000g for 30 min at 4 °C (Sorvall RC-5B centrifuge, rotor SS-34; Sorvall Heraeus, Kendro Laboratory Products), and the supernatant fraction was discarded. Erythrocytes were washed 3 times with 40 mL ice-cold Tris buffer, and the final erythrocyte membrane pellet was stored at –80 °C for further fatty acid analysis.

fatty acid composition determination
We used the transesterification method developed by Lepage and Roy (19) and adapted by Masood et al. (20) with minor modifications. Briefly, in glass tubes containing 100 µL plasma, we added 20 µL of the internal standard solution (providing 50 mg C19:0/L) and 2 mL of a methanol/toluene (4/1, vol/vol) mixture. Samples were vortex-mixed for 30 s, and we carefully added 200 µL acetyl chloride dropwise while swirling the tubes. Tubes were capped under nitrogen and transferred to a heating oven at 103 °C for 90 min. After cooling, the tubes were uncapped, and samples were treated by addition of 5 mL 6% K2CO3 and of 3 mL hexane. Recapped tubes were vortex-mixed for 1 min and centrifuged for 7 min at 500g. We collected the upper organic phase and repeated the extraction procedure on the lower phase by adding 1 mL hexane. The two upper combined phases were washed with 1 mL distilled water, followed by a new centrifugation. The final organic phase was collected and evaporated under nitrogen to dryness at 40 °C. The dry residue was then redissolved in 200 µL hexane and transferred to capped vials for further analysis.

Fatty acid methyl esters were separated by use of a gas chromatograph (HP6890; Hewlett-Packard-Agilent) equipped with a capillary column (DB-FFAP), 30 m by 0.25 mm ID by 0.25 µm (J and W Scientific, Agilent Technologies) and identified and quantified by mass spectrometry (MS 5973; Agilent Technologies). The temperature program was as follows: initial at 130 °C with a 1-min hold; ramp: 4 °C/min to 178 °C, 1 °C/min to 210 °C, and 40 °C/min to 245 °C with a 7-min hold. Helium was used as carrier gas, under a flow rate of 2.5 mL/min. We performed selected ion monitoring and identified fatty acid methyl esters both by their respective retention times and by comparison with spectra of pure reference substances. Intra- and interassay CVs were <3% and <5.7%, respectively (except for {gamma}-linolenate methyl ester, with 9.3%).

statistical analysis
Results are expressed as mean ± SD or median (interquartile range). Statistical data were analyzed by nonparametric Kruskal-Wallis test, and between-groups comparisons were evaluated by Mann-Whitney U test. We performed statistical analyses by use of Statview software (Abacus Concepts). Null hypothesis was rejected at P <0.05.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
population characteristics
Table 1 summarizes clinical characteristics of CF patients, whose mean age (SD) at time of sampling was 17.5 (11.3) years. Age and male sex distribution were not statistically different between CF and control groups. Moreover, the CF cohort displays an equal sex distribution (64 males, 60 females; P >0.99). Homozygosity for the {Delta}F508 mutation was present in almost half of the CF cohort, and pancreatic insufficiency was diagnosed in approximately 80% of the CF population (n = 97). Lung function was assessed in 101 of 124 patients. FEV1 averaged 81.7% (25.5%) of predicted. Approximately 20% of patients displayed chronic P. aeruginosa colonization (n = 25).


View this table:
[in this window]
[in a new window]

  		Table 1. Population characteristics of healthy controls and CF patients.

plasma fatty acid composition
Plasma fatty acid composition significantly differed in CF patients compared with healthy controls (Table 2 ). Overall, mean values of saturated fatty acid (SFA) and monounsaturated fatty acid (MUFA) concentrations were found to be increased, whereas PUFAs were globally decreased in CF compared with healthy controls. Among PUFAs, mean concentrations of linoleic acid (LA, C18:2 n-6), AA (C20:4 n-6), and DHA (C22:6 n-3) were decreased, whereas those of {gamma}-linolenic acid (GLA, C18:3 n-6), dihomo-{gamma}-linolenic acid (DGLA, C20:3 n-6), docosatetraenoic acid (DTA, C22:4 n-6), docosapentaenoic acid n-6 (DPA6, C22:5 n-6), EPA (eicosapentaenoic acid, C20:5 n-3), DPA3 (C22:5 n-3), and ETA (eicosatrienoic acid, C20:3 n-9), the latter considered a good marker of EFAD, were found to be increased in CF patients compared with healthy controls.


View this table:
[in this window]
[in a new window]

  		Table 2. Median (interquartile range) plasma fatty acid profile in healthy controls and CF patients according to pancreatic status (g/100 g total FA).

erythrocyte membrane fatty acid composition
As observed with the plasma fatty acid profile, CF patients presented disturbances of fatty acid composition of the erythrocyte membranes (Table 3 ). Accordingly, MUFA concentrations were increased and PUFA concentrations were globally decreased in CF patients compared with healthy controls. LA and DHA concentrations were decreased in membrane preparations from erythrocytes, as they were in plasma samples. There was also a decreasing trend in AA concentrations (P = 0.051). As observed in plasma, DGLA, DPA6, EPA, DPA3, and ETA concentrations were increased in CF patients compared with healthy controls.


View this table:
[in this window]
[in a new window]

  		Table 3. Median (interquartile range) erythrocyte membrane fatty acid profile in healthy controls and CF patients according to pancreatic status (g/100 g total FA).

influence of pancreatic status on pufa profiles
As illustrated in Tables 2Up and 3Up , pancreatic status was shown to exert distinct effects on the fatty acid profile in CF, with pancreatic insufficiency usually accentuating disturbances. Indeed, concentrations of PUFA, LA, and AA were decreased in both plasma and erythrocyte membranes in pancreatic insufficient patients compared with pancreatic sufficient patients. Moreover, GLA, DGLA, DPA6, and EPA concentrations in plasma as well as DGLA, DPA6, and EPA concentrations in erythrocyte membranes were increased in pancreatic insufficient patients. Interestingly, ETA concentrations, which were globally increased in the whole CF population compared with the control group, were found to be higher in the presence of pancreatic insufficiency. Conversely, DHA and DPA3 concentrations, which were respectively reduced and increased in CF compared with healthy controls, did not appear to be affected by pancreatic status.

influence of patient sex on pufa profiles
We next assessed the influence of sex on the fatty acid composition of plasma and erythrocyte membranes in CF patients. It is important to note that none of the monitored clinical characteristics, such as age, prevalence of {Delta}F508 homozygosity, chronic P. aeruginosa colonization, pancreatic insufficiency, degree of lung function, or nutritional status, differed between male and female CF patients (data not shown). However, some influences of sex on the fatty acid profile, diverging from those revealed for pancreatic status, were detected in the CF group but not observed in the control group. Indeed, DHA concentrations [medians (interquartiles)], which were shown to be reduced in the whole CF group, appeared to be much more reduced in the subgroup of male patients compared with female patients in both plasma [1.28 (0.58) vs 1.64 (0.69) g/100 g of total FA, respectively; P = 0.002] and erythrocytes [3.51 (1.24) vs 4.06 (1.30) g/100 g of total FA, respectively; P = 0.005]. Interestingly, plasma {alpha}-linolenic acid (ALA) concentrations, which were not different between the whole CF population and the healthy control group, were found to be significantly reduced in male compared with female CF patients [0.46 (0.36) vs 0.57 (0.43) g/100 g of total FA, respectively; P = 0.009]. Moreover, plasma ETA concentrations, which were found to be almost 3-fold higher in the whole CF group compared with healthy controls (Tables 2Up and 3Up ), were much more increased in male than in female CF patients, suggesting male-dependent EFAD in CF [0.51 (0.57) vs 0.32 (0.44) g/100 g of total FA, respectively; P = 0.005].

laXdha product
The LAxDHA product (arbitrary units) was decreased in both plasma and erythrocyte membranes from CF patients compared with healthy controls. This decrease was more prominent in the presence of pancreatic insufficiency (Tables 2Up and 3Up and Fig. 1 ). Moreover, male CF patients displayed a lower LAxDHA product in plasma [28.98 (13.61) vs 36.84 (18.52), respectively; P = 0.002] and erythrocyte membranes [27.40 (12.70) vs 31.71 (11.89), respectively; P = 0.013] than female CF patients.


Figure 1
View larger version (7K):
[in this window]
[in a new window]

  		Figure 1. Distribution of LAxDHA product values (arbitrary units) expressed as median ± interquartile range (in box) and 10th and 90th percentiles (bars) in plasma (P) and erythrocyte membranes (RBC) in healthy controls (n = 80) and CF patients according to pancreatic status.

CF pancreatic sufficient (PS) patients (n = 27) are significantly different from healthy controls, P <0.03. CF pancreatic insufficient (PI) patients (n = 97) are significantly different from both healthy controls, P <0.0001, and CF PS patients, P <0.03. Differences between groups were determined by Mann-Whitney test.

aa/dgla ratio
The AA/DGLA ratio (arbitrary units) was decreased in both plasma and erythrocyte membranes from CF patients compared with healthy controls. Interestingly, values similar to those detected in the control group were found in pancreatic sufficient patients, whereas pancreatic insufficient patients displayed significantly lower values for this ratio (Tables 2Up and 3Up and Fig. 2 ). We observed no significant influence of sex on the AA/DGLA ratio.


Figure 2
View larger version (7K):
[in this window]
[in a new window]

  		Figure 2. Distribution of AA/DGLA ratio values (arbitrary units) expressed as median ± interquartile range (in box) and 10th and 90th percentiles (bars) in plasma (P) and erythrocyte membranes (RBC) in healthy controls (n = 80) and CF patients according to pancreatic status.

CF pancreatic insufficient (PI) patients (n = 97) are significantly different from both healthy controls and CF pancreatic sufficient (PS) patients (n = 27), P <0.0001. Differences between groups were determined by Mann-Whitney test.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Disturbed plasma and tissue fatty acid compositions have been well described in CF patients (8). However, some major discrepancies in PUFA variations have been observed in the blood compartments analyzed in some studies (8). With the use of GC-MS, which provides improved characterization and sensitivity, and the inclusion in our study of a large cohort of CF patients, we have demonstrated characteristic and profound alterations in both plasma and erythrocyte membranes and the influence of pancreatic status and sex on these alterations.

As in the literature background results (8), we observed some significant changes in the plasma PUFA composition of our CF population. Although changes were statistically significant, physiological repercussions could not be established during this study. Reduced concentrations of LA in plasma and tissues have been found in CF patients (8)(12)(13) as well as in our CF population. Concentrations of AA have proved more variable in different studies, including values that were significantly decreased (21)(22) or not different (12)(22)(23)(24)(25) compared with controls. Our CF patients presented a slight but significant decrease in plasma AA concentrations. Concerning DHA concentrations, we noted a significant decrease, as previously described in some studies (12)(21) but not in others (22)(23). The discrepancies in AA and DHA plasma concentrations, from the previous studies, can be explained in part by the low number of CF patients enrolled (8). Because of the size of our cohort of CF patients, we were able to find significant decreases in AA and DHA concentrations in plasma as often observed when these PUFAs were analyzed from plasma phospholipids instead of total plasma lipids (8)(26). However, the low DHA concentrations seem not to depend on pancreatic status. The presence of pancreatic insufficiency impaired the n-6 fatty acid concentrations, LA and AA, whereas the negative effect of CF on DHA concentrations was independent of pancreatic status.

Tissues from mammals seem to have a highly regulated specific membrane lipid composition (27)(28). The observed decrease for CF patients in the bioavailability of PUFAs, and notably AA and DHA, induces important changes in membrane fatty acid composition to the detriment of cell functionality. These lasting alterations can be involved, in part, in the progression in the physiopathology of specific tissues altered by CF. On the assumption that the fatty acid composition of erythrocyte cell membrane may be similar to that of other organs and tissues (29), erythrocyte seems to be a reliable surrogate of the accretion of PUFAs and particularly n-3 fatty acids from exogenous dietary sources as well as endogenous synthesis (30). In studies in which fatty acid composition was monitored in erythrocyte membranes (8)(23)(24)(31)(32)(33), no abnormality was detected in AA and DHA concentrations, whereas the most consistent alterations seemed to be detected in LA content. When specific membrane fractions, such as phosphatidylethanolamines and phosphatidylcholines, were examined, however, a decrease in both AA and DHA was observed (34)(35). In our whole CF population, we reported a decrease in LA concentrations. DHA concentrations were also reduced, and there was a trend for a decrease in AA concentrations (P = 0.051). Pancreatic insufficient CF patients presented decreases in LA and DHA concentrations, and the decrease in AA concentration was shown to be significant (P = 0.006). As with the results in plasma, the main feature of pancreatic sufficient CF patients was a significant decrease in DHA concentrations.

Disturbances in essential fatty acid metabolism were evident in CF patients. Indeed, altered DHA concentrations in both plasma and erythrocyte membranes were the main feature of pancreatic sufficient CF patients. These reductions could result neither from fat malabsorption, because concentrations of the two essential fatty acids, LA and ALA, were not altered, nor from a decrease in desaturase activities, since n-6 long-chain PUFAs were not altered. So an increase in DHA metabolism could explain lower concentrations. In pancreatic insufficient CF patients, the situation was completely different, with reductions in LA, AA, and DHA concentrations along with increases in GLA, DGLA, DPA6, EPA, and DPA3 concentrations. The trivial explanation for reduced LA concentrations could be fat malabsorption, but because ALA concentrations in these patients were not different than those of healthy controls, the fat malabsorption seems not to be the only factor involved. A decrease in desaturase activities or acceleration in n-6 PUFA resulting from an accentuated catabolism of AA into eicosanoids (36) may contribute as associated cofactors to explain these reduced LA concentrations. The observed decrease in DHA concentrations in both plasma and erythrocyte membranes, independent of pancreatic status, can reflect an accentuated catabolism of DHA. Indeed, DHA is the precursor of a series of mediators, including resolvins, docosatrienes, and neuroprotectins, that are involved in the resolution phase of inflammation, enhanced in CF patients (37)(38). So DHA exerts a cardinal influence on cell functionality, and a decrease of DHA bioavailability in CF patients may have deleterious effects on tissue functionality and particularly on pulmonary and pancreatic functions.

In regard to DHA concentrations, we found a significant influence of sex in CF patients, whereas no similar effect was observed in controls. Indeed, male CF patients presented significantly lower concentrations of DHA in both plasma and erythrocyte membranes. To our knowledge, it is the first time that a sex difference for DHA concentrations in CF patients is reported; according to our data, it cannot be explained by a difference in age, weight, BMI, FEV1, or IgG concentrations. A previous study has shown a sex difference for some fatty acids in plasma nonesterified fatty acid fraction, but unfortunately n-3 fatty acids were not investigated (39). Further investigations are required to understand this phenomenon.

The LAxDHA product was recently proposed as a predictive diagnostic marker to differentiate CF patients from non-CF controls (40). In this study, the LAxDHA product was the most effective parameter, of 11 fatty acid parameters, in measuring plasma fatty acid status to discriminate CF patients from healthy controls in a blinded way. The authors concluded that a value ≤40 for this product could be used as a clinical cutoff for CF. In our study, although the LAxDHA product is significantly decreased in pancreatic sufficient CF patients and further decreased in pancreatic insufficient CF patients, this product seems not discriminating enough to easily distinguish pancreatic sufficient CF patients from healthy controls with this cutoff.

The AA/DGLA ratio is usually described as an index of {Delta}5 desaturase activity, the enzyme that converts DGLA to AA in the essential fatty acid metabolism (8)(34). Thus, a decrease in this ratio can be related to a decrease or inhibition of {Delta}5 desaturase activity. However, in CF patients, a decrease in this ratio could also reflect enhanced {Delta}5 desaturase activity, with increased catabolism of AA due to its transformation into proinflammatory metabolites such as eicosanoids (36). In our CF patients, the AA/DGLA ratio was decreased only in pancreatic insufficient CF patients, so this ratio allows differentiation of CF patients according to pancreatic status. Accordingly, the AA/DGLA ratio may be a useful predictive marker for the presence of pancreatic insufficiency in CF patients, and it seems to be more discriminatory than the LAxDHA product. Indeed, the area under the curve (AUC), calculated from comparative ROC curves, was found to be larger in plasma and erythrocyte membranes for the AA/DGLA ratio than for the LAxDHA product (not shown).

In conclusion, we analyzed plasma and erythrocyte membrane fatty acid compositions from a large cohort of CF patients to address some questions arising from observed discrepancies in fatty acid profiles in the literature. The similar changes observed in both plasma and erythrocyte membranes indicate that plasma would be a logistically simpler sample for laboratory determination of fatty acid composition in CF patients. Our data clearly demonstrate that pancreatic status plays a cardinal role in the observed decreases in LA, AA, and DHA concentrations in blood lipids. However, the decrease of DHA concentrations seems to be independent of pancreatic status, since pancreatic sufficient CF patients also had this feature. We demonstrate that the LAxDHA product cannot be a diagnostic marker for pancreatic sufficient CF patients and that the AA/DGLA ratio can be useful as a predictive marker for pancreatic insufficiency. Finally, the observed decrease of DHA concentrations in male CF patients compared with female CF patients requires further investigation.


   Acknowledgments
 
Grant/funding Support: T.C.C. is a postdoctoral fellow of FSR (Fonds Spéciaux de Recherche) from the Université Catholique de Louvain. This work was supported by grants from the FSR, the Belgian CF Association, and the French CF Association, Vaincre la Mucoviscidose.

Financial Disclosures: None declared.

Acknowledgments: Critical reading of the manuscript by Pr. Jean Lebacq is gratefully acknowledged. The authors thank Françoise Wustefeld and Véronique Hubaux for their help. The authors also thank all the healthy controls and the CF patients of this study.


   Footnotes
 
1 Nonstandard abbreviations: CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; PUFA, polyunsaturated fatty acid; EFAD, essential fatty acid deficiency; AA, arachidonic acid; DHA, docosahexaenoic acid; FEV1, forced expiratory volume in 1 s; BMI, body mass index; SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; LA, linoleic acid; GLA, {gamma}-linolenic acid; DGLA, dihomo-{gamma}-linolenic acid; DTA, docosatetraenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; ETA, eicosatrienoic acid (mead acid); ALA, {alpha}-linolenic acid.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, et al. Identification of the cystic fibrosis gene: genetic analysis. Science (Wash DC) 1989;245:1073-1080.[Abstract/Free Full Text]
  2. Foskett JK. ClC and CFTR chloride channel gating. Annu Rev Physiol 1998;60:689-717.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  3. Lukacs GL, Mohamed A, Kartner N, Chang XB, Riordan JR, Grinstein S. Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. EMBO J 1994;13:6076-6086.[Web of Science][Medline] [Order article via Infotrieve]
  4. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918-951.[Abstract/Free Full Text]
  5. Sinaasappel M, Stern M, Littlewood J, Wolfe S, Steinkamp G, Heijerman HG, et al. Nutrition in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2002;1:51-75.[CrossRef][Medline] [Order article via Infotrieve]
  6. Carroccio A, Pardo F, Montaldo G, Iapichino L, Soresi M, Averna MR, et al. Use of famotidine in severe exocrine pancreatic insufficiency with persistent maldigestion on enzymatic replacement therapy: a long-term study in cystic fibrosis. Dig Dis Sci 1992;37:1441-1446.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  7. Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration 2000;67:117-133.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  8. Coste TC, Armand M, Lebacq J, Lebecque P, Wallemacq P, Leal T. An overview of monitoring and supplementation of omega 3 fatty acids in cystic fibrosis. Clin Biochem 2007;40:511-520.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  9. Rosenlund ML, Kim HK, Kritchevsky D. Essential fatty acids in cystic fibrosis. Nature (Lond) 1974;251:719.[Medline] [Order article via Infotrieve]
  10. Rivers JP, Hassam AG. Defective essential-fatty-acid metabolism in cystic fibrosis. Lancet 1975;306:642-643.[CrossRef]
  11. Freedman SD, Katz MH, Parker EM, Laposata M, Urman MY, Alvarez JG. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr (–/–) mice. Proc Natl Acad Sci U S A 1999;96:13995-14000.[Abstract/Free Full Text]
  12. Freedman SD, Blanco PG, Zaman MM, Shea JC, Ollero M, Hopper IK, et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004;350:560-569.[Abstract/Free Full Text]
  13. Strandvik B, Gronowitz E, Enlund F, Martinsson T, Wahlstrom J. Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis. J Pediatr 2001;138:650-655.
  14. Rosentein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 1998;132:589-595.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  15. Meyts I, Wuyts W, Proesmans M, De Boeck K. Variability of fecal pancreatic elastase measurements in cystic fibrosis. J Cyst Fibros 2002;1:265-268.[CrossRef][Medline] [Order article via Infotrieve]
  16. Kalnins D, Durie PR, Pencharz P. Nutritional management of cystic fibrosis patients. Curr Opin Clin Nutr Metab Care 2007;10:348-354.[Web of Science][Medline] [Order article via Infotrieve]
  17. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983;127:725-734.[Web of Science][Medline] [Order article via Infotrieve]
  18. Cole TJ, Feeman JV, Preece MA. Body mass index reference curves for the UK, 1990. Arch Dis Child 1995;73:25-29.[Abstract/Free Full Text]
  19. Lepage G, Roy CC. Direct transesterification of all classes of lipids in a one-step reaction. J Lipid Res 1986;27:114-120.[Abstract]
  20. Masood A, Stark KD, Salem N, Jr. A simplified and efficient method for the analysis of fatty acid methyl esters suitable for large clinical studies. J Lipid Res 2005;46:2299-2305.[Abstract/Free Full Text]
  21. Thompson GN. Relationship between essential fatty acid levels, pulmonary function and fat absorption in pre-adolescent cystic fibrosis children with good clinical scores. Eur J Pediatr 1989;30:327-329.
  22. Lepage G, Levy E, Ronco N, Smith L, Galeano N, Roy CC. Direct transesterification of plasma fatty acids for the diagnosis of essential fatty acid deficiency in cystic fibrosis. J Lipid Res 1989;30:1483-1490.[Abstract]
  23. Underwood BA, Denning CR, Navab M. Polyunsaturated fatty acids and tocopherol levels in patients with cystic fibrosis. Ann N Y Acad Sci 1972;203:237-247.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  24. Chase HP, Dupont J. Abnormal levels of prostaglandins and fatty acids in blood of children with cystic fibrosis. Lancet 1978;312:236-238.[CrossRef]
  25. Farrell PM, Mischler EH, Engle MJ, Brown J, Lau SM. Fatty acid abnormalities in cystic fibrosis. Pediatr Res 1985;19:104-109.[Web of Science][Medline] [Order article via Infotrieve]
  26. Benabdeslam H, Garcia I, Bellon G, Gilly R, Revol A. Biochemical assessment of the nutritional status of cystic fibrosis patients treated with pancreatic enzymes. Am J Clin Nutr 1998;67:912-918.[Abstract]
  27. Thewke D, Kramer M, Sinensky MS. Transcriptional homeostatic control of membrane lipid composition. Biochem Biophys Res Commun 2000;273:1-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  28. Aguilar PS, de Mendoza D. Control of fatty acid desaturation: a mechanism conserved from bacteria to humans. Mol Microbiol 2006;62:1507-1514.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  29. Poppitt SD, Kilmartin P, Butler P, Keogh GF. Assessment of erythrocyte phospholipid fatty acid composition as a biomarker for dietary MUFA, PUFA or saturated fatty acid intake in a controlled cross-over intervention trial. Lipids Health Dis 2005;4:30.[CrossRef][Medline] [Order article via Infotrieve]
  30. Cao J, Schwichtenberg KA, Hanson NQ, Tsai MY. Incorporation and clearance of omega-3 fatty acids in erythrocyte membranes and plasma phospholipids. Clin Chem 2006;52:2265-2272.[Abstract/Free Full Text]
  31. Farrell PM, Bieri JG, Fratantoni JF, Wood RE, di Sant’Agnese PA. The occurrence and effects of human vitamin E deficiency: a study in patients with cystic fibrosis. J Clin Invest 1977;60:233-241.[Web of Science][Medline] [Order article via Infotrieve]
  32. Hubbard VS, Dunn GD. Fatty acid composition of erythrocyte phospholipids from patients with cystic fibrosis. Clin Chim Acta 1980;102:115-118.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  33. De Vizia B, Raia V, Spano C, Pavlidis C, Coruzzo A, Alessio M. Effect of an 8-month treatment with omega-3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosis. J Parenter Enteral Nutr 2003;27:52-57.[Abstract/Free Full Text]
  34. Biggemann B, Laryea MD, Schuster A, Griese M, Reinhardt D, Bremer HJ. Status of plasma and erythrocyte fatty acids and vitamin A and E in young children with cystic fibrosis. Scand J Gastroenterol 1988;23:135-141.
  35. Innis SM, Davidson GF, Chen A, Dyer R, Melnyk S, James SJ. Increased plasma homocysteine and S-adenosylhomocysteine and decreased methionine is associated with altered phosphatidylcholine and phosphatidylethanolamine in cystic fibrosis. J Pediatr 2003;143:351-356.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  36. Strandvik B, Svensson E, Seyberth HW. Prostanoid biosynthesis in patients with cystic fibrosis. Prostaglandins Leukot Essent Fatty Acids 1996;55:419-425.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  37. Das UN. Essential fatty acids: biochemistry, physiology and pathology. Biotechnol J 2006;1:420-439.[CrossRef][Medline] [Order article via Infotrieve]
  38. Serhan CN, Arita M, Hong S, Gotlinger K. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. Lipids 2004;39:1125-1132.[Web of Science][Medline] [Order article via Infotrieve]
  39. Rogiers V, Dab I, Crokaert R, Vis HL. Long chain non-esterified fatty acid pattern in plasma of cystic fibrosis patients and their parents. Pediatr Res 1980;14:1088-1091.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  40. Batal I, Ericsoussi MB, Cluette-Brown JE, O’Sullivan BP, Freedman SD, Savaille JE, Laposata M. Potential utility of plasma fatty acid analysis in the diagnosis of cystic fibrosis. Clin Chem 2007;53:78-84.[Abstract/Free Full Text]



The following articles in journals at HighWire Press have cited this article:


Home page
 J. Nutr.Home page
M. Mimoun, T. C. Coste, J. Lebacq, P. Lebecque, P. Wallemacq, T. Leal, and M. Armand
Increased Tissue Arachidonic Acid and Reduced Linoleic Acid in a Mouse Model of Cystic Fibrosis Are Reversed by Supplemental Glycerophospholipids Enriched in Docosahexaenoic Acid
J. Nutr., December 1, 2009; 139(12): 2358 - 2364.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2007.094623v1
54/2/388    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coste, T. C.
Right arrow Articles by Leal, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coste, T. C.
Right arrow Articles by Leal, T.
Related Collections
Right arrow Nutrition

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS